GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Q2 FY27 Consolidated Net Profit INR 3,250.68 Million

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 03 Nov 2026, 01:41 PM IST  ·  BSE ID: c2158b0d-59d8-4ae7-adcb-15a877d4c7e2
View Original BSE Filing (PDF)
💡
In Simple Terms
Emcure Pharmaceuticals announced its latest financial results, showing an increase in revenue and profit for the September 2026 quarter.
🤖 AI Summary
  • Emcure Pharmaceuticals reported consolidated revenue from operations of INR 28,204.71 million for the quarter ended September 30, 2026 (Q2 FY27).
  • Consolidated Profit for Q2 FY27 stood at INR 3,250.68 million, compared to INR 2,513.70 million in Q2 FY26.
  • Total consolidated income for the quarter reached INR 28,237.25 million, an increase from INR 22,729.45 million in Q2 FY26.
  • Basic Earnings Per Share (EPS) for Q2 FY27 was INR 17.16, up from INR 12.85 in Q2 FY26.
  • The Board meeting for approving these results commenced at 12:48 p.m. (IST) and concluded at 13:30 p.m. (IST) on November 03, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Revenue from operations (Q2 FY27)
28,204.71 million
24.26%
Consolidated Profit for the period (Q2 FY27)
3,250.68 million
29.32%
Consolidated Basic EPS (Q2 FY27)
17.16
33.54%
Consolidated Total Income (Q2 FY27)
28,237.25 million
24.29%
Consolidated Revenue from operations (Half-year FY27)
54,009.18 million
23.57%
Consolidated Profit for the period (Half-year FY27)
6,175.61 million
32.45%
🏢 How This Affects the Company
📈
Business Impact
The increase in revenue from operations indicates expansion in sales and market reach, with Q2 FY27 consolidated revenue growing to INR 28,204.71 million.
💰
Financial Impact
Profit for the period increased to INR 3,250.68 million in Q2 FY27 from INR 2,513.70 million in Q2 FY26, positively impacting the company's earnings.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported financial performance, as it reflects the company's operational health and profitability for the quarter and half-year ended September 30, 2026.
🔍
Management Signal
The approval and disclosure of these results signal management's routine compliance with regulatory requirements and transparency regarding financial performance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check for sustained revenue and profit growth
Investor conference calls — listen for management commentary on performance drivers
Future regulatory filings — observe disclosures on business expansion or new product launches
LOW RISK The filing reports routine quarterly financial results with positive growth metrics, indicating no immediate elevated risks.
💡 Investor Takeaway
Emcure Pharmaceuticals Limited reported consolidated revenue from operations of INR 28,204.71 million for Q2 FY27, a 24.26% increase YoY. Consolidated net profit for the period reached INR 3,250.68 million, up 29.32% YoY. This confirms continued growth in the company's financial performance.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated revenue from operations grew to INR 28,204.71 million in Q2 FY27, a 24.26% increase from INR 22,698.22 million in Q2 FY26.
  • Consolidated Profit for the period increased by 29.32% to INR 3,250.68 million in Q2 FY27 compared to INR 2,513.70 million in Q2 FY26.

⚠️ Concerns

  • Cost of materials consumed rose to INR 6,421.28 million in Q2 FY27, up from INR 4,204.61 million in Q2 FY26, a 52.71% increase.
  • Employee benefit expenses increased to INR 4,347.10 million in Q2 FY27, an increase of 13.02% from INR 3,846.21 million in Q2 FY26.
📅 Company Track Record
Emcure Pharmaceuticals' Q1 FY27 consolidated revenue was INR 25,804.47 million, with a YoY growth of 22.8%. The current Q2 FY27 results show continued strong revenue growth of 24.26% YoY, building on previous quarter's performance.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Emcure Pharmaceuticals' consolidated revenue from operations for Q2 FY27?
Emcure Pharmaceuticals reported consolidated revenue from operations of INR 28,204.71 million for the quarter ended September 30, 2026 (Q2 FY27).
What was Emcure Pharmaceuticals' consolidated net profit for Q2 FY27?
The consolidated Profit for the period for Emcure Pharmaceuticals was INR 3,250.68 million for Q2 FY27, compared to INR 2,513.70 million in Q2 FY26.
What was the Basic EPS for Emcure Pharmaceuticals in Q2 FY27?
Emcure Pharmaceuticals reported a Basic Earnings Per Share (EPS) of INR 17.16 for Q2 FY27, up from INR 12.85 in the comparable prior period of Q2 FY26.
What was Emcure Pharmaceuticals' consolidated revenue from operations for the half-year ended September 30, 2026?
For the half-year ended September 30, 2026, Emcure Pharmaceuticals' consolidated revenue from operations was INR 54,009.18 million.
What was the total comprehensive income for Emcure Pharmaceuticals in Q2 FY27?
Total comprehensive income for Emcure Pharmaceuticals for Q2 FY27 was INR 3,393.06 million.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.